Vaccine Production Research Articles

Using matrix assisted laser desorption ionisation mass spectrometry combined with machine learning for vaccine authenticity screening

The global population is increasingly reliant on vaccines to maintain population health with billions of doses used annually in immunisation programmes. Substandard and falsified vaccines are becoming more prevalent, caused by both the degradation of authentic vaccines but also deliberately falsified vaccine products. These threaten public health, and the increase in vaccine falsification is now a major concern. There is currently no coordinated global infrastructure or screening methods to monitor vaccine supply chains. In this study, we developed and validated a matrix-assisted laser desorption/ionisation-mass spectrometry (MALDI-MS) workflow that used open-source machine learning and statistical analysis to distinguish authentic and falsified vaccines. We validated the method on two different MALDI-MS instruments used worldwide for clinical applications. Our results show that multivariate data modelling and diagnostic mass spectra can be used to distinguish authentic and falsified vaccines providing proof-of-concept that MALDI-MS can be used as a screening tool to monitor vaccine supply chains.

Reduced aggregation of the Leghorn Male Hepatoma (LMH) cell line in suspension by supplementing dextran sulfate in the media.

The study aimed to improve the efficiency of Leghorn Male Hepatoma (LMH) cells for animal virus vaccine production by transitioning from adherent to suspension culture and evaluating the effects of dextran sulfate (DS) on preventing cell aggregation. The goal was to enhance cell growth, viability, and glucose metabolism and to develop efficient suspension-adapted LMH cells for large-scale vaccine production. LMH cells previously cultured in an adherent state were transferred to 125 mL Erlenmeyer flasks to conduct suspension culture. Cell culture performance, including cell density, viability, and glucose metabolism, during the cultures was measured, along with an assessment of cell aggregation. Additionally, mRNA expression levels of genes associated with cell adhesion and apoptosis were monitored. DS supplementation in suspension culture enhanced cell viability and growth, with higher cell densities and viabilities compared to control media. Additionally, DS supplementation reduced glucose consumption and waste production, indicating improved metabolic efficiency. DS also delayed cell aggregation, possibly by downregulating integrin expression and promoting anti-apoptotic gene expression. However, even after 2 months, cell aggregation persisted in both control and DS-supplemented cultures, suggesting further optimization is needed for LMH cell adaptation to suspension culture. DS supplementation in LMH cell suspension cultures led to notable improvements in cell growth, viability, and glucose metabolism, while also decreasing the cell aggregation.

Analyzing the Profitability's Impact on Firm Value During COVID-19

Amidst the COVID-19 epidemic, the specific impact of pharmaceutical companies' financial prowess on their overall worth remains uncertain. While many studies have explored the correlation between business value and various internal and external factors, the existing literature has not adequately focused on the precise influence of firm profitability on firm value, especially in the context of an epidemic. This article aims to fill a research gap by examining the relationship between profitability and corporate value during the COVID-19 pandemic, specifically focusing on Pfizer. This article utilizes a quantitative analysis technique. This research has developed a quantitative analytical approach to precisely measure the impact of profitability, which is an independent variable, on company value, which is a dependent variable. The investigation indicates a robust and favorable correlation between business value and sales growth. Due to the strong positive association between vaccine revenue and stock prices, it is advisable for corporate directors and strategic planners to emphasize vaccination production and sales.

Multi-epitope Vaccine Design against Grouper Iridovirus (GIV) Using Immuno-bioinformatics Approach

Grouper Iridovirus (GIV) infection induced cell death in grouper spleen cells and caused serious systemic diseases with more than 90% mortality. Therefore, effective strategies are critically needed to prevent economic losses and maintain the sustainability of grouper aquaculture. Using immuno-bioinformatics, this study aimed to create a multi-epitope vaccine (MEV) that would be effective against GIV. The GIV major capsid protein sequences were retrieved from the NCBI proteome database. Out of 284 epitopes, 17 CTL, 12 HTL, and 10 B-cell epitopes were predicted to be antigenic, non-allergenic, and non-toxic. 10 highly antigenic and overlapping epitopes were shortlisted. To generate full-length epitope vaccine candidates, the selected antigenic epitopes were fused with linkers and adjuvants. Four sets of different linker combinations (no linker, GGS, EAAK, GGGS, GPGPG, KK, and AAY) were tested and compared for their antigenicity, allergenicity, and toxicity using several servers. Molecular dynamics simulations with GROMACS were used on the modelled 3D structures to examine their stability. The results of vaccine candidate sequences screening and MD simulation predicted that the structure with GGS linker is relatively stable with a high antigenic index, non-allergenic, and non-toxic. The designed MEV in the present study could be a potential candidate for further vaccine production process against GIV.

Baculoviruses in Integrated Pest Management of Fall Armyworm, (Spodoptera frugiperda) (Lepidoptera: Noctuidae): Structure, Classification and Application

Baculoviruses are crucial biological agents in integrated pest management (IPM), particularly for controlling lepidopteran pests in agriculture. These are highly specific, eco-friendly viruses characterized by rod-shaped nucleocapsids containing a protein-encased genome. The Baculoviridae family comprises four genera: Alphabaculovirus, Betabaculovirus, Gammabaculovirus, and Deltabaculovirus, each targeting specific insect orders. Nucleo polyhedron virus (NPVs) and granuloviruses (GVs) are extensively used in pest management due to their high virulence and specificity, ensuring safety for non-target organisms. Ascoviruses are dsDNA viruses that infect Spodoptera frugiperda larvae, transmitted primarily by parasitoids. Despite high virulence, their use in pest control is limited due to ineffective oral transmission. Combining ascoviruses with other pathogens, such as Bacillus thuringiensis kurstaki (Btk), may enhance their pest control potential. The infection process begins when insect larvae ingest viral occlusion bodies, leading to systemic infection and host death. Despite their narrow host range and slower action compared to chemical insecticides, baculoviruses are invaluable in sustainable agriculture. Their application has expanded beyond pest control to include gene therapy and vaccine production. This review examines the structure, classification, infection process, and current status of baculoviruses in controlling the fall armyworm, Spodoptera frugiperda, a significant agricultural pest. By exploring their potential as a cornerstone in biological pest management, we highlight the importance of baculoviruses in developing sustainable and environmentally friendly pest control strategies. The integration of baculoviruses into IPM programs offers a promising approach to reduce chemical pesticide use, preserve biodiversity, and enhance crop protection, ultimately contributing to more sustainable agricultural practices and food security.

High throughput screening for SARS-CoV-2 helicase inhibitors

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for nearly 7 million deaths worldwide since its outbreak in late 2019. Even with the rapid development and production of vaccines and intensive research, there is still a huge need for specific anti-viral drugs that address the rapidly arising new variants. To address this concern, the National Institute of Allergy and Infectious Diseases (NIAID) established nine Antiviral Drug Discovery (AViDD) Centers, tasked with exploring approaches to target pathogens with pandemic potential, including SARS-CoV-2. In this study, we sought inhibitors of SARS-CoV2 non-structural protein 13 (nsP13) as potential antivirals, first developing a HTS-compatible assay to measure SARS-CoV2 nsP13 helicase activity. Here we present our effort in implementing the assay in a 1,536 well-plate format and in identifying nsP13 inhibitor hit compounds from a ∼650,000 compound library. The primary screen was robust (average Z’ = 0.86 ± 0.05) and resulted in 7,009 primary hits. 1,763 of these compounds upon repeated retests were further confirmed, showing consistent inhibition. Following in-silico analysis, an additional orthogonal assay and titration assays, we identified 674 compounds with IC50 <10 μM. We confirmed activity of independent compound batches from de novo powders while also incorporating multiple counterscreen assays. Our study highlights the potential of this assay for use on HTS platforms to discover novel compounds inhibiting SARS-CoV2 nsP13, which merit further development as an effective SARS-CoV2 antiviral.

Use of MONTANIDE ISA 78 VG as adjuvant for the manufacture of antibacterial vaccines for chickens

Relevance. The use of antimicrobial agents and vaccine prophylaxis are the main ways to prevent and control most diseases of bacterial etiology. At the same time, uncontrolled use of antimicrobial agents without determining the sensitivity of microorganisms, as a rule, does not give the opportunity to obtain a positive therapeutic result. At the same time, a competently designed scheme of inactivated vaccine administration, taking into account the epizootic situation, is an effective and safe tool for controlling bacterial diseases.In this regard, the results of testing of vaccine samples against bacterial diseases of birds based on the modernized oil adjuvant Montanide ISA 78 VG presented in this article are interesting and modern.Methods. Four vaccine samples were manufactured for research based on the oil adjuvant Montanide ISA 78 VG. The first sample of the vaccine is against avian salmonellosis, the second — against avian pasteurellosis, the third — against avian respiratory mycoplasmosis, the fourth — against avian hemophilosis. All manufactured vaccine samples were investigated for sterility, stability and viscosity of the emulsion according to generally accepted methods. To determine the reactogenicity and antigenic activity of the vaccine samples, young egg-laying hens aged 25–40 days were used.Results. Analysis of the obtained results of physical and biological properties of tested inactivated vaccines against bacterial diseases of birds allows us to conclude that the vaccine against respiratory mycoplasmosis of birds made on the basis of adjuvant Montanide ISA 78 VG is a safe and effective immunobiological preparation.

Queuing analysis for improving performance in bacterial vaccine quality control process

The aim of the research is to analyze and improve the performance of the vaccine quality control queuing system to reduce delays and achieve the firm’s long-term goal on vaccine production capacity. The research focuses on the Bacterial Vaccine Quality Control (BVQC) at the largest vaccine manufacturers in Indonesia and Southeast Asia. The vaccines handled by BVQC include TT, DTP, BCG, BioTT, BioTd, DT, Td, and DTP-Hb-Hib. The BVQC operates a queuing system with eight servers, each assigned a fixed task. The existing system experienced delays ranging from 13 % to 61 % from January to June 2022. After identifying the queuing characteristics of the existing system, improvement proposals were suggested by modifying the assignment of the servers. This proposal was then simulated in November 2022, resulting in improved performance with no delays, a reduction in the length of the queue in the system (Lq) from 2.88 to 2.59, and a reduction in the average time spent in the system (Ws) from 0.0099 to 0.0044. The research suggests that modifying server assignments can be an effective method for improving the performance of a queuing system in vaccine quality control. This can lead to reduced delays, optimized queue lengths, and improved overall efficiency, potentially enhancing the firm’s ability to meet vaccine demand in the future.

African vaccine manufacturing - The ecosystem and the Initiative.

N/A

A Rationally Designed H5 Hemagglutinin Subunit Vaccine Provides Broad-Spectrum Protection against Various H5Nx Highly Pathogenic Avian Influenza Viruses in Chickens.

The evolution of the H5 highly pathogenic avian influenza (HPAI) viruses has led to the emergence of distinct groups with genetically similar clusters of hemagglutinin (HA) sequences. In this study, a consensus H5 HA sequence was cloned into the baculovirus expression system. The HA protein was expressed in baculovirus-infected insect cells and utilized as the antigen for the production of an oil emulsion-based H5 avian influenza vaccine (rBacH5Con5Mut). Twenty-one-day-old SPF chickens were immunized with this vaccine and then challenged at 21 days post-vaccination with clade 2.3.2.1, clade 2.3.4.4, and clade 7.2 of H5 HPAI viruses. The sera of vaccinated chickens exhibited high hemagglutination inhibition (HI) titers against the rBacH5 vaccine antigen, while lower HI titers were observed against the different challenge virus H5 hemagglutinins. Furthermore, the rBacH5Con5Mut vaccine provided 100% protection from mortality and clinical signs. Virus isolation results showed that oropharyngeal and cloacal shedding was prevented in 100% of the vaccinated chickens when challenged with clade 2.3.2.1 and clade 2.3.4.4 H5 viruses. When the rBacH5Con5Mut vaccine candidate was administrated at one day of age, 100% protection was demonstrated against the challenge of clade 2.3.4.4 virus at three weeks of age, indicating the potential of this vaccine for hatchery vaccination. Overall, A single immunization of rBacH5Con5Mut vaccine candidate with a consensus HA antigen can protect chickens against different clades of H5 HPAI viruses throughout the rearing period of broiler chickens without a boost, thus fulfilling the criteria for an efficacious broad-spectrum H5 avian influenza vaccine.

Current limitations in predicting mRNA translation with deep learning models

BackgroundThe design of nucleotide sequences with defined properties is a long-standing problem in bioengineering. An important application is protein expression, be it in the context of research or the production of mRNA vaccines. The rate of protein synthesis depends on the 5′ untranslated region (5′UTR) of the mRNAs, and recently, deep learning models were proposed to predict the translation output of mRNAs from the 5′UTR sequence. At the same time, large data sets of endogenous and reporter mRNA translation have become available.ResultsIn this study, we use complementary data obtained in two different cell types to assess the accuracy and generality of currently available models for predicting translational output. We find that while performing well on the data sets on which they were trained, deep learning models do not generalize well to other data sets, in particular of endogenous mRNAs, which differ in many properties from reporter constructs.ConclusionsThese differences limit the ability of deep learning models to uncover mechanisms of translation control and to predict the impact of genetic variation. We suggest directions that combine high-throughput measurements and machine learning to unravel mechanisms of translation control and improve construct design.

A Droplet-Based Microfluidic Platform for High-Throughput Culturing of Yeast Cells in Various Conditions.

Yeast plays a significant role in a variety of fields. In particular, it is extensively used as a model organism in genetics and cellular biology studies, and is employed in the production of vaccines, pharmaceuticals, and biofuels. Traditional "bulk"-based studies on yeast growth often overlook cellular variability, emphasizing the need for single-cell analysis. Micro-droplets, tiny liquid droplets with high surface-area-to-volume ratios, offer a promising platform for investigating single or a small number of cells, allowing precise control and monitoring of individual cell behaviors. Microfluidic devices, which facilitate the generation of micro-droplets, are advantageous due to their reduced volume requirements and ability to mimic in vivo micro-environments. This study introduces a custom-designed microfluidic device to encapsulate yeasts in micro-droplets under various conditions in a parallel manner. The results reveal that optimal glucose concentrations promoted yeast growth while cycloheximide and Cu2+ ions inhibited it. This platform enhances yeast cultivation strategies and holds potential for high-throughput single-cell investigations in more complex organisms.

Analyze the Optimal International Allocation of Vaccine to Maximize Benefit in Terms of Minimizing the Risk of Infection

The COVID-19 pandemic brought the problem of disparities in vaccine production and distribution among nations into sharp focus, as this problem may leave people in low-income countries more vulnerable to the virus. Based on this background, this paper introduces a model that helps donors determine their vaccine donation strategy, aiming to maximize donor benefit by minimizing the risk of infection for their domestic people. Meanwhile, by receiving donated vaccines, the lower-income countries would also benefit, leading to a win-win situation. This model is based on a simplified condition where there are only two countries, and each vaccine is used by domestic people or donated to the other country. By analyzing the effects of the risk of disease, the relative importance of vaccines, and the level of contact between countries, this essay provides an equation that enables the calculation of the optimal number of vaccines that should be consumed by domestic people given the values of parameters. It analyzes the relationship between each parameter and the optimal number. This simple model can be employed to inspire the allocation of resources for other infectious diseases or similar situations.

The Development of Epitope-Based Recombinant Protein Vaccines against SARS-CoV-2.

The COVID-19 pandemic continues to cause infections and deaths, which are attributable to the SARS-CoV-2 Omicron variant of concern (VOC). Moderna's response to the declining protective efficacies of current SARS-CoV-2 vaccines against Omicron was to develop a bivalent booster vaccine based on the Spike (S) protein from the Wuhan and Omicron BA.4/BA.5 strains. This approach, while commendable, is unfeasible in light of rapidly emerging mutated viral strains. PubMed and Google Scholar were systematically reviewed for peer-reviewed papers up to January 2024. Articles included focused on specific themes such as the clinical history of recombinant protein vaccine development against different diseases, including COVID-19, the production of recombinant protein vaccines using different host expression systems, aspects to consider in recombinant protein vaccine development, and overcoming problems associated with large-scale recombinant protein vaccine production. In silico approaches to identify conserved and immunogenic epitopes could provide broad protection against SARS-CoV-2 VOCs but require validation in animal models. The recombinant protein vaccine development platform has shown a successful history in clinical development. Recombinant protein vaccines incorporating conserved epitopes may utilize a number of expression systems, such as yeast (Saccharomyces cerevisiae), baculovirus-insect cells (Sf9 cells), and Escherichia coli (E. coli). Current multi-epitope subunit vaccines against SARS-CoV-2 utilizing synthetic peptides are unfeasible for large-scale immunizations. Recombinant protein vaccines based on conserved and immunogenic proteins produced using E. coli offer high production yields, convenient purification, and cost-effective production of large-scale vaccine quantities capable of protecting against the SARS-CoV-2 D614G strain and its VOCs.

Emerging Market Vaccine Manufacturers: Untapped Potential for Improving Health and Social Outcomes Globally

ABSTRACTThe suboptimal level of vaccine research and development globally contributes to millions of people losing their lives to vaccine‐preventable diseases each year, the vast majority of whom live in developing countries. Vaccine manufacturers based in developing countries are increasingly participating in vaccine research and development to improve the availability of these life‐saving vaccine products. To understand the extent to which these emerging market vaccine manufacturers can contribute to global vaccine research and development, and thus improve health and societal outcomes, we examined the capabilities, priorities, and strategies of these organizations. We identified that emerging market manufacturers often engage in partnerships and solicit external support to alleviate the technical and financial hurdles associated with the complexity and cost of vaccine development. Focusing on unmet medical needs facilitates emerging market manufacturers' access to partners and external support and is critical in establishing a reputation in the global vaccine research and development ecosystem.

COVID-19 Vaccine Effectiveness Studies against Symptomatic and Severe Outcomes during the Omicron Period in Four Countries in the Eastern Mediterranean Region.

Vaccine effectiveness (VE) studies provide real-world evidence to monitor vaccine performance and inform policy. The WHO Regional Office for the Eastern Mediterranean supported a regional study to assess the VE of COVID-19 vaccines against different clinical outcomes in four countries between June 2021 and August 2023. Health worker cohort studies were conducted in 2707 health workers in Egypt and Pakistan, of whom 171 experienced symptomatic laboratory-confirmed SARS-CoV-2 infection. Test-negative design case-control studies were conducted in Iran and Jordan in 4017 severe acute respiratory infection (SARI) patients (2347 controls and 1670 cases) during the Omicron variant dominant period. VE estimates were calculated for each study and pooled by study design for several vaccine types (BBIBP-CorV, AZD1222, BNT162b2, and mRNA-1273, among others). Among health workers, VE against symptomatic infection of a complete primary series could only be computed compared to partial vaccination, suggesting a benefit of providing an additional dose of mRNA vaccines (VE: 88.9%, 95%CI: 15.3-98.6%), while results were inconclusive for other vaccine products. Among SARI patients, VE against hospitalization of a complete primary series with any vaccine compared to non-vaccinated was 20.9% (95%CI: 4.5-34.5%). Effectiveness estimates for individual vaccines, booster doses, and secondary outcomes (intensive care unit admission and death) were inconclusive. Future VE studies will need to address challenges in both design and analysis when conducted late during a pandemic and will be able to utilize the strengthened capacities in countries.

A Review on the Development of Microcarriers for Cell Culture Applications

Microcarrier-based cell culture systems have gained significant attention and popularity in tissue engineering and regenerative medicine. In this culture system, tissue cells are grown as a monolayer on the surface of small solid particles called microcarriers (100 to 300 μm), kept suspended in the culture medium by stirring. This technology has paved the way for creating engineered tissues, one of the cutting-edge topics in tissue engineering and regenerative medicine. Microcarrier-based approaches have been proposed for three-dimensional (3D) cell culture in which cellular morphology and functions are maintained &lt;i&gt;in vivo&lt;/i&gt;. This paper provides an overview of the optimal characteristics such as microcarriers’ size, shape, density and porosity. Various methods of preparation of microcarriers and surface modification techniques have been elaborated. Recent advances and applications of microcarriers in biotechnology fields, like the production of viral vaccines and recombinant proteins, culture and expansion of stem cells (SC), are described.

Uniform Polymeric Nanovaccine Platform for Improving the Availability and Efficacy of Neoantigen Peptides.

Personalized cancer vaccines targeting specific neoantigens have been envisioned as one of the most promising approaches in cancer immunotherapy. However, the physicochemical variability of the identified neoantigens limits their efficacy as well as vaccine manufacturing in a uniform format. Herein, we developed a uniform nanovaccine platform based on poly(2-oxazoline)s (POx) to chemically conjugate neoantigen peptides, regardless of their physicochemical properties. This vaccine system could self-assemble into nanoparticles with uniform size (around 50 nm) and improve antigen accumulation as well as infiltration in the lymph node to increase antigen presentation. In vivo vaccination using this system conjugated with three predicted peptide neoantigen peptides from the MC38 tumor cell line induced 100% robust CD8+ T cell responses and superior tumor clearance compared to free peptides. This POx-based vaccine carrier represents a generalizable approach to increase the availability and efficacy of screened neoantigen peptides for a personalized cancer vaccine.

Determination of DTaP vaccine potency by multiplex immunogenicity testing using electrochemiluminescence

Lot release testing of diphtheria, tetanus and acellular pertussis vaccines traditionally relied on in vivo protection models involving challenge of laboratory animals with toxins. Meanwhile, many labs have switched to serological testing of these vaccines, which is often performed in separate in vivo assays, even if all components were formulated into one vaccine product. Here we describe the results of simultaneous serological potency determination of diphtheria (D), tetanus (T) and acellular pertussis (aP) antigens obtained following immunization of guinea pigs with multicomponent pediatric and booster vaccines from different manufacturers. The 4th World Health Organization (WHO) International Standard (IS) for diphtheria toxoid (No. 07/216) and the 4th WHO IS for tetanus toxoid (No. 08/218) were used as reference preparations. For aP, a pediatric vaccine batch containing the antigens pertussis toxoid, filamentous hemagglutinin, pertactin and fimbriae proteins type 2/3 was established as internal control. Quantification of IgG against D, T and aP antigens in guinea pig sera was performed using a hexaplex electrochemiluminescence immunoassay. We further provide proof-of-concept using experimental vaccine samples lacking or containing reduced amounts of diphtheria toxoid in the presence of full amounts of tetanus and pertussis antigens and alum adjuvant. Importantly, the assay confirmed dose-response relationships for all antigens tested and was able to detect diphtheria out-of-specification batches. The results confirmed the suitability of the protocol for combined serology batch release testing of DTaP combination vaccines as first measure towards implementation of full in vitro testing of DTaP vaccines. This report summarizes the data and the protocol used for validation prior to implementation of this method in routine batch release testing of DTaP vaccines, which led to replacement of in vivo challenge experiments in our laboratory following the 3 R (replace, reduce, refine) principle.

Novel manufacturing process of pneumococcal capsular polysaccharides using advanced sterilization methods.

Pneumococcal disease is caused by Streptococcus pneumoniae, including pneumonia, meningitis and sepsis. Capsular polysaccharides (CPSs) have been shown as effective antigens to stimulate protective immunity against pneumococcal disease. A major step in the production of pneumococcal vaccines is to prepare CPSs that meet strict quality standards in immunogenicity and safety. The major impurities come from bacterial proteins, nucleic acids and cell wall polysaccharides. Traditionally, the impurity level of refined CPSs is reduced by optimization of purification process. In this study, we investigated new aeration strategy and advanced sterilization methods by formaldehyde or β-propiolactone (BPL) to increase the amount of soluble polysaccharide in fermentation supernatant and to prevent bacterial lysis during inactivation. Furthermore, we developed a simplified process for the CPS purification, which involves ultrafiltration and diafiltration, followed by acid and alcohol precipitation, and finally diafiltration and lyophilization to obtain pure polysaccharide. The CPSs prepared from formaldehyde and BPL sterilization contained significantly lower level of residual impurities compared to the refined CPSs obtained from traditional deoxycholate sterilization. Finally, we showed that this novel approach of CPS preparation can be scaled up for polysaccharide vaccine production.